Nissay Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.18M | Buy |
152,835
+6,281
| +4% | +$209K | 0.02% | 344 |
|
|
2026
Q1 | $4.41M | Buy |
146,554
+2,917
| +2% | +$93.8K | 0.02% | 336 |
|
|
2025
Q4 | $4.48M | Buy |
143,637
+344
| +0.2% | +$8.47K | 0.02% | 340 |
|
|
2025
Q3 | $2.89M | Buy |
143,293
+655
| +0.5% | +$11.5K | 0.02% | 426 |
|
|
2025
Q2 | $2.39M | Buy |
142,638
+4,252
| +3% | +$68.6K | 0.01% | 469 |
|
|
2025
Q1 | $2.13M | Sell |
138,386
-663
| -0.5% | -$11.8K | 0.01% | 498 |
|
|
2024
Q4 | $3.17M | Buy |
139,049
+1,575
| +1% | +$28.7K | 0.02% | 411 |
|
|
2024
Q3 | $2.48M | Buy |
137,474
+3,597
| +3% | +$63K | 0.02% | 477 |
|
|
2024
Q2 | $2.18M | Buy |
133,877
+3,066
| +2% | +$47.2K | 0.01% | 477 |
|
|
2024
Q1 | $1.85M | Buy |
130,811
+1,976
| +2% | +$24.9K | 0.01% | 528 |
|
|
2023
Q4 | $1.35M | Buy |
128,835
+5,098
| +4% | +$47.6K | 0.01% | 566 |
|
|
2023
Q3 | $1.26M | Buy |
123,737
+4,658
| +4% | +$43.4K | 0.01% | 559 |
|
|
2023
Q2 | $897K | Sell |
119,079
-1,770
| -1% | -$14.4K | 0.01% | 636 |
|
|
2023
Q1 | $1.07M | Sell |
120,849
-4,589
| -4% | -$45.4K | 0.01% | 590 |
|
|
2022
Q4 | $1.14M | Sell |
125,438
-6,053
| -5% | -$52.8K | 0.01% | 564 |
|
|
2022
Q3 | $1.06M | Buy |
131,491
+5,103
| +4% | +$45.1K | 0.01% | 575 |
|
|
2022
Q2 | $950K | Sell |
126,388
-1,194
| -0.9% | -$10.4K | 0.01% | 588 |
|
|
2022
Q1 | $1.2M | Buy |
127,582
+2,233
| +2% | +$18.6K | 0.01% | 576 |
|
|
2021
Q4 | $1M | Buy |
125,349
+5,097
| +4% | +$46K | 0.01% | 641 |
|
|
2021
Q3 | $1.17M | Buy |
120,252
+4,436
| +4% | +$41.5K | 0.01% | 592 |
|
|
2021
Q2 | $1.15M | Sell |
115,816
-6,278
| -5% | -$66.5K | 0.01% | 602 |
|
|
2021
Q1 | $1.41M | Buy |
122,094
+1,709
| +1% | +$19.6K | 0.01% | 525 |
|
|
2020
Q4 | $1.16M | Buy |
120,385
+3,292
| +3% | +$31.5K | 0.02% | 548 |
|
|
2020
Q3 | $1.05M | Sell |
117,093
-30,947
| -21% | -$327K | 0.02% | 523 |
|
|
2020
Q2 | $1.82M | Sell |
148,040
-20,266
| -12% | -$229K | 0.04% | 386 |
|
|
2020
Q1 | $1.51M | Buy |
168,306
+68,700
| +69% | +$704K | 0.04% | 370 |
|
|
2019
Q4 | $976K | Buy |
99,606
+1,439
| +1% | +$12.8K | 0.02% | 532 |
|
|
2019
Q3 | $675K | Sell |
98,167
-65,237
| -40% | -$500K | 0.02% | 595 |
|
|
2019
Q2 | $1.51M | Buy |
163,404
+28,462
| +21% | +$343K | 0.04% | 404 |
|
|
2019
Q1 | $2.12M | Sell |
134,942
-8,117
| -6% | -$143K | 0.06% | 350 |
|
|
2018
Q4 | $2.21M | Buy |
143,059
+3,680
| +3% | +$75.4K | 0.07% | 325 |
|
|
2018
Q3 | $3M | Buy |
139,379
+17,497
| +14% | +$406K | 0.08% | 292 |
|
|
2018
Q2 | $2.96M | Buy |
121,882
+812
| +0.7% | +$16.6K | 0.09% | 286 |
|
|
2018
Q1 | $2.07M | Buy |
121,070
+44,026
| +57% | +$860K | 0.06% | 326 |
|
|
2017
Q4 | $1.46M | Buy |
+77,044
| New | +$1.16M | 0.04% | 348 |
|
Other funds holding TEVA
HIIFS
PF
CI
MMH
MIFH
LIM
Nissay Asset Management's TEVA Position: Q2 2026 in Review
Nissay Asset Management increased its Teva Pharmaceuticals (TEVA) stake by 4.3% in Q2 2026, buying an estimated $209K and bringing the position to 152,835 shares worth $5.18M. The position accounts for 0.02% of the portfolio, ranked #344.
Nissay Asset Management first reported a position in TEVA in Q4 2017 and has held it in 35 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.
- Nissay Asset Management held 152,835 shares of Teva Pharmaceuticals worth $5.18M as of Q2 2026.
- Nissay Asset Management bought 6,281 Teva Pharmaceuticals shares in Q2 2026, an estimated $209K.
- Teva Pharmaceuticals made up 0.02% of Nissay Asset Management's portfolio in Q2 2026, its #344 holding.
- Nissay Asset Management first reported a position in Teva Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.
Based on Nissay Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.